Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
SEATTLE and SOUTH SAN FRANCISCO, Calif., May 08, 2017 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report first quarter 2017 financial results and provide a corporate update after the close of U.S. financial markets on Wednesday, May 17, 2017. Immune Design management will host a webcast and conference call at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on May 17, 2017.
The live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at http://ir.immunedesign.com/events.cfm and will be archived there for 30 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 20090178.
About Immune Design
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the primary foci of Immune Design's ongoing immuno-oncology clinical programs, are products of its two synergistic discovery platforms, ZVex® and GLAAS®. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.
Media Contact Julie Rathbun Rathbun Communications [email protected] 206-769-9219 Investor Contact Shari Annes Annes Associates [email protected] 650-888-0902
